Genome sequencing identified rare NR6A1 variants in families with colobomatous microphthalmia, missing vertebrae and congenital kidney anomalies. In silico modeling, cell assays, and zebrafish knockdown/rescue experiments support pathogenicity and define NR6A1 as a pleiotropic developmental regulator.
0:00Welcome to Base by Base, the paper cast that brings genomics to you wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. It's great to be here So to start off today, I want you to imagine a patient, uh, sitting in an ophthalmologist's exam chair.
0:15Right, just a regular eye exam. Exactly. And they've come in because of a missing piece of tissue in their eye. It's a potentially blinding condition called a coloboma. Right, which is quite serious. Yeah, it often presents as this like keyhole shaped gap in the iris, or sometimes a missing structural component deep within the retina.
0:35But and here is where it gets strange. As the medical team looks closer at this patient's history, they realize this person is harboring a couple of, well, seemingly unrelated anomalies. Unrelated how?
0:47This exact same patient is also missing a vertebra in their spine, and they are entirely missing one of their kidneys. Oh, wow. Yeah, clinical medicine has historically treated a presentation like that as just, you know, a tragic sequence of isolated coincidences.
1:01Just bad luck. essentially, yeah. An ocular defect, a spinal anomaly, and unilateral renal agenesis. That would typically send a patient to 3 completely different specialists. Specialists who, frankly, might never cross-reference their notes.
1:17Okay, let's unpack this. Wait, actually, let me rephrase that. Okay, let's unpack this. Because if you think about human embryogenesis, like constructing a massive commercial high rise. This isn't the equivalent of a storm rolling in and, I don't know, coincidentally shattering a window, snapping a steel support beam, and bursting a plumbing pipe.
1:35So definitely not a random storm. Right. This is like finding a single microscopic flaw in the master blueprint that simultaneously instructs the builders to skip that specific window, completely ignore the structural beam on the 5th floor, and just forget to lay the plumbing for a specific bathroom.
1:54That's a great way to put it. So what really happens when a master regulatory gene misfires during the earliest days of human development. Well, that is the core of the mystery we are analyzing today for this deep dive.
2:05Yeah. We are looking at how a singular uh, molecular misprint can just ripple outward during embryogenesis. Disrupting everything at once. Exactly. Disrupting the formation of the eye, the spine, and the kidneys simultaneously.
2:19Today, we celebrate the work of the National Eye Institute, University College, London, and the Genomics England team, who have advanced our understanding of complex developmental genetics by combining deep clinical observation with massive genomic databases.
2:34It really is a profound example of collaborative molecular detective work. It really is And, you know, to appreciate the scale of this research. We have to look at the specific clinical problem acting as the focal point here, which is UVL coloboma.
2:47Right, the ID effect. Yeah. So during early gestation. The eye develops from an optic vessel that invaginates, basically folds in on itself, to form a cup like structure. Okay. There is a seam at the bottom of this cup called the optic fissure, and it must fuse completely to form a healthy pressurized eye.
3:05And if it doesn't fuse. When that fusion fails, a gap remains, that's the color boma, and it accounts for up to 10% of childhood blindness globally. 10%. Where? And for you listening, if you follow the genomic space, you are likely familiar with how challenging congenital blindness can be to map.
3:25Oh, absolutely. Because despite knowing UVL colaboma has a strong genetic component, a vast majority of these patients never receive a definitive molecular diagnosis. Right. The underlying genetic culprits have just remained elusive for a long time.
3:39Until now. Well, yeah. Researchers at the National Eye Institute have been tracking a specific cohort of families exhibiting this exact constellation of symptoms. The UVL colaboma, missing thoracic or lumbar vertebrae, and the congenital kidney anomalies.
3:54You got it. And they observed an autosomal dominant inheritance pattern, meaning it passes directly from parent to child. But the severity varies, right? Yes. And what's fascinating here is the incomplete penetrance across these families.
4:06What do you mean by that? Well, the research team identified a mother in one of the families who was visually completely asymptomatic. Wait, really? She had no vision issues at all. None. She had no idea she possessed a mild form of the I defect or that she was actually missing a thoracic vertebra entirely.
4:23Missing a whole bone in her spine. Yeah. Not until she underwent thorough clinical screening is part of this study. That is wild. I mean, the adaptability of the human body in masking those structural deficits is just remarkable.
4:36truly is. Missing a bone in the spinal column without any overt phenotypic signs. It really highlights how complex, incomplete penetrance can be when you're tracking these conditions. Definitely. And to solve a diagnostic puzzle, where symptoms are hidden like that, and the phenotypic targets stand completely different biological systems, looking at a single candidate gene based on a single symptom is just insufficient.
5:00Right. You can't just look at one gene. You have to look at the whole instruction manual. Precisely. A broader, completely unbiased approach is necessary. So the researchers utilize a genome 1st methodology.
5:12Okay break that down for us. Rather than just sequencing the affected families sitting in their clinic, they took their suspect variants and queried the UK 100,000 genomes project database. The UK 100 KGP.
5:25Exactly. This allowed them to essentially reverse engineer the diagnostic process. Oh, so. They searched a massive population database for the specific genetic signatures first. Then they analyzed the clinical phenotypes of the individuals carrying those signatures.
5:43Regardless of why those individuals were originally sequenced in the 1st place. Exactly. See, the power of a genome 1st deep dive into a database of that magnitude is that it removes the initial ascertainment bias.
5:55Right, completely removes it. You aren't just looking at the people who walked into an eye clinic. You are looking at the entire population. Yes, and once they identify the suspect variance. The team leveraged alpha fold.
6:06The AI tool, right? Yeah, to build three-dimensional models of the mutant proteins, mapping out the exact structural failures in silico. So they modeled it on a computer first? Correct. Then they transition from in silico modeling to in vitrocellular biology to observe these structural failures in actual action.
6:24Testing it in human cells. Yeah, HEK 293 cells. They introduce the suspect proteins into these cells, utilizing fluorescent tags. Ah, so they could literally see where the proteins were going under a microscope.
6:36Exactly, tracking their intracellular localization under fluorescence microscopy, but they didn't stop there. They went to an animal model. Yes. To bring the investigation full circle. They moved into an invivo model.
6:48They utilized Morpholinos to knock down or disable the equivalent suspect genes in zebrafish embryos. Okay, wait, I have to push back on the direct translational value of that specific step. Why is that?
7:00Wow, I mean, a zebra fish doesn't possess a human spine or human kidneys. Modeling complex human renal and vertetabral anomalies in a tiny fish seems like an extraordinary biological leap, doesn't it? It sounds like a leaf sure, but the conservation of these early developmental pathways across vertebrate species makes a zebra fish an ideal model.
7:20Because of evolution. Right. The fundamental genetic software, dictating the segmentation of the body axis, or the imagination of the optic cup, is shared among humans, mice, and zebrafish due to common evolutionary ancestry.
7:34Okay. And the specific gene family involved operates on early developmental time scales that are perfectly mirrored in a zebra fish embryo. They develop really fast, right? Super fast. Highly visible summites appear within the 1st 24 hours of fertilization.
7:48Okay, so we are essentially observing the same biological hammer and nails being used to build the foundational framework. Yes. Even if the final architecture looks vastly different between the 2 species.
7:58That's spot on. Manipulating that shared foundation in the fish reveal the direct phenotypic consequences of a specific genetic disruption almost immediately. Okay, so what was the culprit? What did they find?
8:09The team identified 6 rare variants in a gene called NR6 A1. NR6A1. Yes. It encodes an orphan nuclear receptor. And prior to this, NR6A1 was primarily known for its role in animal embryonic development, specifically in axial elongation.
8:26Animal spines. Yeah, in fact, it is a gene that has historically been selected for in agricultural breeding programs to produce livestock. like pigs with longer vertebral columns. Wait, pigs? Are you serious?
8:39I am. And this study is the 1st time NR6A1 has been definitively linked to human eye and kidney organogenesis. Identifying an agricultural livestock gene as the primary architect behind human childhood blindness and renal failure is, well, it's a profound shift in how we understand its biological role.
8:58It really is. And the alpha fold models provided the mechanical explanation for this failure. Okay, let's hear the mechanics. They analyzed a specific mutation labeled R92W. In the healthy, wild type protein, position 92 contains an amino acid with a positive charge.
9:15Which it needs for something specific. Yes, it is necessary to electrostatically bind to negatively charge DNA sequences. The mutation changes that. Right. The R92W mutation substitutes that positively charged amino acid with tryptophan.
9:29And tryptophan is different. Very. As a bulky hydrophobic amino acid, tryptophan fundamentally disrupts the binding interface. The electrostatic interaction is completely lost. Ah, so it replaces a positively charged amino acid with a hydrophobic one, so the protein can no longer anchor itself to the DNA.
9:48Exactly. So rather than just a loss of magnetic attraction. It is like trying to force a square peg into a round biochemical lock. That's good visual. The physical geometry changes, preventing the molecular machinery from gripping the DNA sequence it is supposed to regulate.
10:03You got it. So we know the R92W mutation destroys the DNA binding domain. Did the intracellular tracking experiments with the fluorescent tags reveal a similar mechanical breakdown for the other variants?
10:16Actually, no, the in vitro tracking revealed a completely distinct mechanism of failure for a different variant called R436C. Okay, how did that one fail? Well, a functional NR6A1 protein is synthesize in the cytoplasm, and then it must translocate or travel into the cell's nucleus to act as a transcription factor.
10:36To regulate the expression of target genes. Right. But the fluorescence microscopy demonstrated that the R436C mutant protein was trapped entirely within the cytoplasm. Oh, wow. Here's where it gets really interesting.
10:51Because if the nucleus is the command tent where critical strategic decisions are made, this mutated transcription factor is a general who has been permanently locked out of the tent. Exactly right. The protein might be structurally capable of issuing commands, but without access to the nuclear environment where the DNA resides, those regulatory commands never reach their target genes, the entire developmental strategy just collapses.
11:17That is exactly what happens. The biological function is negated not through a structural inability to bind DNA, like the 1st variant. But through a failure in geographic localization. Yes, and this leads directly to the zebra fish in vivo validation, which proved the causality of these specific failures.
11:34So what happened when they knocked out the fish versions of the gene? Well, the zebra fish ortholics of the gene are called NR6A1A, and NR6A1B. And when they use morpholinos to knock them down, the resulting phenotypes directly mirror the human clinical presentation.
11:51In what way? They produced embryos with microphalmia, which are tiny eyes, simulating the coloboma defect. Okay. They also developed flattened or entirely missing somites, which are the precursor structures to vertebrae.
12:04Missing vertebrae, check. And they lacked essential embryonic kidney markers. Plus their entire body axes were severely curved. So they got the tiny eyes, the missing somites, the absent kidney markers and curved body axes.
12:17Recreating the human phenotype and the zebra fish is a strong indicator, but the rescue experiment is what cements the etiology, right? Absolutely. The aha moment. When the researchers microinjected, healthy, wild type human, NR 6A, one MRNA, into the mutant zebrafish.
12:34The developmental trajectory is totally normalized. It fixed them. It did. The human transcript successfully orchestrated the proper formation of the fish's eyes, somites, and body axis. However, when they injected human MRNA, carrying the specific R 92W or R 436C variants found in the patients.
12:53The exact genetic typos. Right. When they injected those, the rescue completely failed. The embryos retain the severe developmental defects. Definitively proving these specific typos caused the disease.
13:05Exactly. It confirms that these precise sequence alterations in NR6A1 are the direct cause of the syndromeic presentation. So what does this all mean? The underlying molecular mechanism has been mapped, demonstrating exactly how the regulatory machinery breaks down.
13:20How does this finding alter the clinical landscape for that patient sitting the exam chair? It necessitates a fundamental shift in diagnostic protocols. This research establishes a brand new medical classification.
13:31Oculovertebral renal syndrome, or OVR syndrome. OVR syndrome. Yes. Symptoms that were previously charted as just idiopathic anomalies now possess a defined molecular ideology. Meaning we know the exact cause.
13:44Right, from a practical standpoint, if a pediatric ophthalmologist, diagnoses a uveal coloboma in a child's eye, the standard of care must expand. They need to look elsewhere. Exactly. They should now actively initiate imaging and screening for occult, spinal, and renal malformations.
14:01Because catching a silent anomaly, much like that asymptomatic mother who is missing a vertebra, allows for proactive management. Identifying a unilateral kidney defect early in childhood, simply because an eye exam prompted a broader scan, could prevent significant renal complications later in life.
14:20That clinical integration is vital, though we must contextualize the scope of these findings, you know, note the limitations. Right. It doesn't explain every case. No, it doesn't. The study indicates that mutations in NR6A1 account for roughly one.3 to one.
14:364% of families within these specific colaboma cohorts. So a small targeted subset. Yes, indicating significant genetic heteroriginity still exists within colaboma diagnoses. There is still much to learn.
14:48And mining large scale population sets like the UK 100 KGP inherently introduces complex secondary findings that require careful interpretation, right? Definitely. For example, some database patients identified with NR6A1 variants, presented with additional clinical features.
15:06Like what? Including intellectual disabilities. Current data is insufficient to determine whether neurological impairment is an atypical manifestation of OVR syndrome extending beyond the primary triad of symptoms.
15:19Or if it just represents a distinct overlapping genetic issue in those specific individuals. Exactly. Expanding the global cohort of identified cases is critical to fully defining the phenotypic spectrum.
15:31Furthermore, the exact downstream genetic targets of NR6A1 still require comprehensive mapping. We have identified the regulatory general, but we lack the complete roster of the biological troops receiving the orders.
15:45That's a great callback, yes. The paper highlights ongoing investigations into the relationship between NR6A1 and retinoic acid signaling. Retinoc acid, okay. Yes. It is a critical signaling molecule that regulates anterior posterior axis patterning during embryogenesis.
16:01Influencing both ocular and renal development. Right. Understanding how NR6A1 modulates or intersects with retinoic acid ingredients will really clarify the intermediate steps between the initial genetic misfire and the final anatomical defects.
16:16Got it. If we connect this to the bigger picture, this research is a profound demonstration of pleotropy. Pleiatropy. The concept that a single genetic locus influences multiple seemingly unrelated phenotypic traits.
16:30Yes. It directly challenges the simplistic notion of isolated developmental pathways. Biological systems are frequently modeled with modular assumptions. Like a specific gene network for ocular development and an entirely separate network for renal organogenesis.
16:45But NR6A1 illustrates that a single transcription factor can act as a foundational architect for geographically distinct and functionally independent regions of the developing embryo. To sum this all up for our listeners, the establishment of OVR syndrome proves that the eye, the spine, and the kidneys share a critical early development architect in the NR6A one gene.
17:07A master switch. Right. By combining deep clinical evaluations with global genomic databases, researchers can connect seemingly isolated birth defects into a unified genetic diagnosis. This raises an important question.
17:20What does this mean for how we view other isolated congenital defects? Could they actually be the quiet whispers of much larger, undiscovered genetic syndromes waiting for us to connect the dots? It brings up a fascinating possibility regarding the future of gene editing tools like CRISPR too.
17:38If a single gene acts as an early stage master switch for such diverse anatomical features, utilizing targeted therapies to correct or alter these specific master architects could be incredibly powerful.
17:50But it would also carry the profound risk of unintended off-target developmental consequences across multiple organ systems. You fix the eye, but what happens to the kidney? It's a lot to think about. It really is.
18:01This episode was based on an open access article under the CCBY 4.0 license. You can find a direct link to the paper and the license in our episode description. If you enjoyed this, follow or subscribe in your podcast app and leave a 5 star rating.
18:16If you'd like to support our work, use the donation link in the description. Now stay with us for an original track created especially for this episode and inspired by the article you've just heard about.
18:26Thanks for listening and join us next time as we explore more science base by base.
